The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models-Reference-Cited by-同舟云学术

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

Published:2014-08-19 Issue:3 Volume:6 Page:1736-1752
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Bladt Friedhelm,Friese-Hamim Manja,Ihling Christian,Wilm Claudia,Blaukat Andree

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

http://www.mdpi.com/2072-6694/6/3/1736/pdf

Reference36 articles.

1. Met provides essential signals for liver regeneration;Borowiak;Proc. Natl. Acad. Sci. USA,2004

2. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers;Sakata;Cell Growth Differ.,1996

3. Progress in cancer therapy targeting c-Met signaling pathway;Jung;Arch. Pharm. Res.,2012

4. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma;You;Hepatology,2011

5. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy;Phytomedicine;2024-06

2. Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence;JCO Precision Oncology;2024-02

3. Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities;Bioorganic Chemistry;2024-01

4. Clinically conserved genomic subtypes of gastric adenocarcinoma;Molecular Cancer;2023-09-06

5. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates;Investigational New Drugs;2023-07-06